Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

J. Zhou; Y.-L.A. Chau; J.W. Yoo; S. Lee; K. Ng; E.C. Dee; T. Liu; A.K.C. Wai; Q. Zhang; G. Tse

doi:10.1016/j.clon.2022.03.006

Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

J. Zhou, Y.-L.A. Chau, J.W. Yoo, S. Lee, K. Ng, E.C. Dee, T. Liu, A.K.C. Wai, Q. Zhang, G. Tse

Department of Data Science

Research output: Journal Publications and Reviews › Letter

11 Citations (Scopus)

Original language	English
Pages (from-to)	e316-e317
Journal	Clinical Oncology
Volume	34
Issue number	7
Online published	20 Mar 2022
DOIs	https://doi.org/10.1016/j.clon.2022.03.006
Publication status	Published - Jul 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access Output

10.1016/j.clon.2022.03.006

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

Zhou, J., Chau, Y.-LA., Yoo, J. W., Lee, S., Ng, K., Dee, E. C., Liu, T., Wai, A. K. C., Zhang, Q., & Tse, G. (2022). Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses. Clinical Oncology, 34(7), e316-e317. https://doi.org/10.1016/j.clon.2022.03.006

@article{a0dae80d85a44519811978f1a395aa31,

title = "Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses",

author = "J. Zhou and Y.-L.A. Chau and J.W. Yoo and S. Lee and K. Ng and E.C. Dee and T. Liu and A.K.C. Wai and Q. Zhang and G. Tse",

year = "2022",

month = jul,

doi = "10.1016/j.clon.2022.03.006",

language = "English",

volume = "34",

pages = "e316--e317",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier Ltd.",

number = "7",

}

Zhou, J, Chau, Y-LA, Yoo, JW, Lee, S, Ng, K, Dee, EC, Liu, T, Wai, AKC, Zhang, Q & Tse, G 2022, 'Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses', Clinical Oncology, vol. 34, no. 7, pp. e316-e317. https://doi.org/10.1016/j.clon.2022.03.006

TY - JOUR

T1 - Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors

T2 - A Propensity Score Matched Study with Competing Risk Analyses

AU - Zhou, J.

AU - Chau, Y.-L.A.

AU - Yoo, J.W.

AU - Lee, S.

AU - Ng, K.

AU - Dee, E.C.

AU - Liu, T.

AU - Wai, A.K.C.

AU - Zhang, Q.

AU - Tse, G.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85131828161&partnerID=8YFLogxK

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85131828161&origin=recordpage

U2 - 10.1016/j.clon.2022.03.006

DO - 10.1016/j.clon.2022.03.006

M3 - Letter

C2 - 35321832

SN - 0936-6555

VL - 34

SP - e316-e317

JO - Clinical Oncology

JF - Clinical Oncology

IS - 7

ER -

Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Cite this